Gunderson Capital Management LLC Acquires 554 Shares of Eli Lilly and Company $LLY

Gunderson Capital Management LLC increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 5.6% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 10,375 shares of the company’s stock after acquiring an additional 554 shares during the period. Eli Lilly and Company accounts for about 3.2% of Gunderson Capital Management LLC’s holdings, making the stock its 15th biggest holding. Gunderson Capital Management LLC’s holdings in Eli Lilly and Company were worth $12,005,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in LLY. Turtle Creek Wealth Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 3.0% during the 3rd quarter. Turtle Creek Wealth Advisors LLC now owns 28,640 shares of the company’s stock worth $33,138,000 after buying an additional 822 shares during the period. WealthPlan Investment Management LLC boosted its stake in Eli Lilly and Company by 4.7% in the 3rd quarter. WealthPlan Investment Management LLC now owns 11,287 shares of the company’s stock valued at $13,060,000 after purchasing an additional 508 shares during the period. SBE LLC DBA Cedar Cove Wealth Partners increased its position in Eli Lilly and Company by 7.3% during the 3rd quarter. SBE LLC DBA Cedar Cove Wealth Partners now owns 709 shares of the company’s stock worth $820,000 after buying an additional 48 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors lifted its holdings in shares of Eli Lilly and Company by 19.9% during the third quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors now owns 1,647 shares of the company’s stock worth $1,906,000 after buying an additional 273 shares in the last quarter. Finally, Nvwm LLC raised its stake in Eli Lilly and Company by 0.4% in the 3rd quarter. Nvwm LLC now owns 3,328 shares of the company’s stock worth $3,851,000 after purchasing an additional 14 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the sale, the chief accounting officer owned 1,526 shares in the company, valued at approximately $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares of the company’s stock, valued at $14,131,250. The trade was a 29.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,500 shares of company stock valued at $15,958,170 over the last quarter. 0.14% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of analyst reports. Bank of America lifted their price target on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a “buy” rating in a research report on Friday, July 10th. Sanford C. Bernstein increased their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a research note on Tuesday, July 14th. JPMorgan Chase & Co. lifted their price target on Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the company an “overweight” rating in a research note on Monday, September 28th. BMO Capital Markets reissued an “outperform” rating on shares of Eli Lilly and Company in a research note on Thursday, October 1st. Finally, Morgan Stanley upped their price target on Eli Lilly and Company from $1,419.00 to $1,430.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1,313.43.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Omvoh data strengthen Lilly’s immunology franchise. In the LUCENT-2 trial, 27.7% of ulcerative-colitis patients achieved comprehensive disease control after one year, including symptomatic, endoscopic and histologic remission, normalized biomarkers and no corticosteroid use. In the VIVID-1 Crohn’s disease trial, 20.4% achieved corticosteroid-free deep remission. The results also included patients who had previously failed biologic therapies, potentially supporting Omvoh’s commercial positioning. Omvoh clinical data
• Positive Sentiment: Pipeline expansion adds longer-term growth potential. Lilly announced oncology collaborations with Adlai Nortye and Prelude Therapeutics, including evaluation of Adlai’s investigational AN4035 with cetuximab. The partnerships broaden Lilly’s cancer research pipeline and exposure to the growing oncology market. Adlai Nortye collaboration
• Neutral Sentiment: Additional pipeline updates provide background support. Lilly is advancing studies of donanemab in India and lebrikizumab in eczema, while investors remain focused on the potential of retatrutide and other next-generation weight-loss treatments.
• Neutral Sentiment: Upcoming earnings could add volatility. Lilly will report third-quarter 2026 results on October 29. Expectations center on continued strong revenue and earnings growth, particularly from its diabetes and obesity medicines. Lilly earnings announcement
• Negative Sentiment: Valuation remains a risk. After a substantial multiyear rally and trading near its 52-week high, Lilly’s premium valuation leaves the stock dependent on continued exceptional growth and successful pipeline execution. Speculation about a stock split is not a fundamental catalyst.

Eli Lilly and Company Price Performance

LLY opened at $1,253.94 on Friday. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The firm’s fifty day moving average price is $1,178.66 and its two-hundred day moving average price is $1,106.93. Eli Lilly and Company has a 1 year low of $783.85 and a 1 year high of $1,292.65. The company has a market capitalization of $1.18 trillion, a price-to-earnings ratio of 42.08, a P/E/G ratio of 1.58 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $1.98. The firm had revenue of $22.97 billion during the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The business’s revenue was up 47.7% compared to the same quarter last year. During the same period last year, the firm posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, analysts anticipate that Eli Lilly and Company will post 34.28 earnings per share for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.